Targets › HDAC
14 programs from 13 companies in 29 trials: 22 Phase 2, 4 Phase 1, 3 Phase 3; Oncology, Other, Metabolic and endocrine; next expected readout Dec 2026.
Open in Phaseline: the race on HDAC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| HUYABIO International | HBI-8000 Histone deacetylase inhibitor | HDAC | Phase 3 | Unresectable or Metastatic Melanoma | Dec 2026 |
| Chinese PLA General Hospital | Chidamide PD-1 checkpoint inhibitor | HDAC, PDCD1 | Phase 3 | Newly Diagnosed Acute Myeloid Leukemia (AML); Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma; Acute Monocytic Leukemia; Relapsed/Refractory Acute Myeloid Leukemia … | Jun 2027 |
| BeBetter Med | Ifupinostat Hydrochloride for Injection (BEBT-908) Histone deacetylase (HDAC) inhibitor | HDAC | Phase 3 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Dec 2028 |
| The First Affiliated Hospital of Soochow University | Chidamide Histone deacetylase inhibitor | HDAC | Phase 2 | Acute Monocytic Leukemia; Acute Myeloid Leukemia; Acute Myeloid Leukemia, Adult; Adult T-cell Leukemia/Lymphoma … | Dec 2026 |
| Tianjin Medical University Cancer Institute and Hospital | Chidamide Histone deacetylase (HDAC) inhibitor | HDAC, HDAC (class I/II) | Phase 2 | Diffuse Large B-Cell Lymphoma-Recurrent; Metastatic Pancreatic Cancer; Diffuse Large B-Cell Lymphoma (DLBCL); Neuroblastoma (NB) | Dec 2026 |
| The First Hospital of Jilin University | Chidamide Histone deacetylase inhibitor | HDAC | Phase 2 | Metastatic Colorectal Cancer; Peripheral T Cell Lymphoma | Jan 2027 |
| Liu Xiufeng | Chidamide Histone deacetylase (HDAC) inhibitor | HDAC | Phase 2 | Pancreatic Cancer, Adult | May 2027 |
| The First Affiliated Hospital of Xiamen University | chidaniline Histone deacetylase inhibitor | HDAC | Phase 2 | Acute Myeloid Leukemia | Jun 2027 |
| China Medical University, China | Chidamide Histone deacetylase (HDAC) inhibitor | HDAC | Phase 2 | Small Cell Lung Cancer | Oct 2027 |
| Nanfang Hospital, Southern Medical University | Chidamide Histone deacetylase inhibitor | HDAC | Phase 2 | Acute Lymphoblastic Leukemia | Jan 2028 |
| University of California, Los Angeles | Fimepinostat HDAC and PI3K inhibitor | HDAC, PIK3CA | Phase 2 | Cushing Disease | Jan 2029 |
| Massachusetts General Hospital | Citarinostat Histone deacetylase (HDAC) inhibitor | HDAC | Phase 1 | Smoldering Multiple Myeloma | Feb 2027 |
| The First Affiliated Hospital of Soochow University | Ifupinostat Hydrochloride (BEBT-908) HDAC inhibitor | HDAC | Phase 1 | B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | Aug 2028 |
| CG Pharmaceuticals | Ivaltinostat Histone deacetylase (HDAC) inhibitor | HDAC | Phase 1 | Metastatic Pancreatic Adenocarcinoma | – |
Acute Myeloid Leukemia (3) Acute Monocytic Leukemia (2) Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma (2) Small Cell Lung Cancer (2) Acute Myeloid Leukemia, Adult (1) Adult T-cell Leukemia/Lymphoma (1) Multiple Myeloma (1) Pancreatic Cancer, Adult (1) Metastatic Pancreatic Adenocarcinoma (1) B-cell Precursor Acute Lymphoblastic Leukemia (ALL) (1) Metastatic Colorectal Cancer (1) Peripheral T Cell Lymphoma (1)
small molecule (7), antibody (5), mixed (2)
The First Affiliated Hospital of Soochow University (2) Liu Xiufeng (1) CG Pharmaceuticals (1) The First Hospital of Jilin University (1) Chinese PLA General Hospital (1) BeBetter Med (1) Tianjin Medical University Cancer Institute and Hospital (1) China Medical University, China (1) The First Affiliated Hospital of Xiamen University (1) HUYABIO International (1) University of California, Los Angeles (1) Nanfang Hospital, Southern Medical University (1) Massachusetts General Hospital (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.